NIHR reveals phase 1/2 trial to evaluate an investigational vaccine for mpox in the UK
More than 3,700 cases of mpox have been identified in the UK since May 2022
Read More
Tag: mpox vaccine
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
